Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences, Inc. (ASMB)
Last assembly biosciences, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.assemblybio.com/investor-relations
Company Research
Source: GlobeNewswire
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – – Phase 2 initiation for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, anticipated by end of 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2025, and recent highlights. “2025 was a pivotal year for the Company, and we anticipate another strong year ahead,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “Compelling Phase 1b data across ABI-5366 and ABI-1179 led to an early decision by Gilead to license the HPI program, validating the strength of our science and
Show less
Read more
Impact Snapshot
Event Time:
ASMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASMB alerts
High impacting Assembly Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ASMB
News
- Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences GAAP EPS of -$0.55 beats by $3.01, revenue of $72.3M beats by $35.02M [Seeking Alpha]Seeking Alpha
- Assembly Biosciences (NASDAQ:ASMB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors [Yahoo! Finance]Yahoo! Finance
ASMB
Sec Filings
- 3/19/26 - Form S-3
- 3/19/26 - Form S-8
- 3/19/26 - Form 10-K
- ASMB's page on the SEC website